Bridge RNA: A new gene editing technique to rival CRISPR
This issue of our newsletter is supported by Inpart.
Discovered only a decade ago, CRISPR has revolutionized the world of gene editing.
But it has limitations. While it is ideal for breaking problematic genes and making small edits, it is not very useful when it comes to inserting whole genes or large chunks of DNA.
Now, though, scientists have come up with a new gene editing technique that could finally overcome these limitations, allowing scientists to insert, delete, or flip large segments of DNA.
This new technique is made possible thanks to the discovery of a molecule called bridge RNA.
To find out more, read the full article: “Bridge RNA: A new gene editing technique that could overcome the limitations of CRISPR”
A MESSAGE FROM OUR SPONSOR INPART
Webinar - What’s the future of food and agriculture R&D?
Join us on Wednesday 24th July 4pm CEST for a conversation with experts from EIT Food and Carrot Ventures. In this online event, we will discuss current and future R&D trends aimed at sustainably feeding global populations, including exclusive insights from our Global Challenge R&D trends report.
🔥 More noteworthy articles from this week:
Although around 190 million women and girls have been diagnosed with endometriosis around the world, patients still suffer an average delay of eight years for diagnosis. However, there is hope for endometriosis care, as clinical trials have shown promise and new drug targets have been discovered.
The companies Formation Bio, Isotopen Technologien München, and Marea Therapeutics bagged the biggest private biotech investments in June 2024, while, around the world, oncology and central nervous system players attracted the biggest funding rounds overall.
Parkinson’s disease is a condition that can impair motor function, and it affects about 10 million people worldwide. Currently, treatments for Parkinson’s help manage symptoms but it is yet to be cured. However, rigorous research could boost therapeutic options for people across different stages of the disease.
Unlike other industries, biotech startups often require substantial initial capital to support extensive R&D, clinical trials, and regulatory approvals before generating any revenue. This high-risk, high-reward environment makes navigating the biotech startup funding landscape particularly complex. In this article, we provide a comprehensive guide to the various funding options available to startups.
Portugal has a rich biotech ecosystem that is rapidly growing. The biotech industry in the country is particularly strong in the area of medical biotech and is supported by the presence of Bial, the largest pharmaceutical company in the country, with headquarters in the Porto area. In this article, we take a look at seven of the biotech companies driving innovation in Portugal.
As the field of radiotherapeutics is currently such a hot topic, we discussed the subject with Ken Herrmann, a radiopharmaceutical academic expert who is Professor of Nuclear Medicine at the Universitätsklinikum Essen, in Essen Germany, and two people from the company Molecular Partners: Patrick Amstutz, who is a co-founder and the CEO, and Dani Steiner, SVP of R&D.
In Europe’s evolving biopharmaceutical landscape, the rapid expansion of advanced therapies like cell and gene therapies (CGT) is reshaping the industry. These treatments have the potential to revolutionize healthcare and enhance patient outcomes, underscoring the urgency of their development.
💡Enjoying these articles? Never miss a single publication of Labiotech by becoming a part of our community! Click here to join our mailing list.